Table 2. Univariate analysis for progression-free survival and overall survival.
| Progression-free survival | Overall survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| n. pts | n. events | Median PFS (months) (95% CI) | HR (95% CI) | p | n. events | Median OS (months) (95% CI) | HR (95% CI) | p | |
| Overall | 335 | 260 | 14.2 (12.1–17.2) | - | 193 | 32.7 (27.1–36.4) | - | ||
| Age | |||||||||
| < 63 years | 157 | 123 | 14.4 (10.8–18.7) | 1.00 | 83 | 34.5 (29.1–50.1) | 1.00 | ||
| ≥ 63 years | 178 | 137 | 14.2 (10.4–17.2) | 1.12 (0.88–1.43) | 0.353 | 110 | 27.1 (20.3–35.7) | 1.31 (0.99–1.75) | 0.061 |
| ECOG PS | |||||||||
| 0–1 | 309 | 236 | 14.9 (13.3–18.4) | 1.00 | 171 | 33.9 (29.1–40.6) | 1.00 | ||
| 2 | 25 | 24 | 3.0 (2.4–5.6) | 3.63 (2.37–5.57) | < 0.0001 | 22 | 6.5 (2.7–9.6) | 4.50 (2.86–7.09) | < 0.0001 |
| Histotype | |||||||||
| Clear cell | 315 | 243 | 14.3 (12.4–17.4) | 1.00 | 179 | 33.6 (27.8–37.3) | 1.00 | ||
| Papillary | 14 | 11 | 7.1 (3.9–31.5) | 1.36 (0.74–2.49) | 0.321 | 9 | 13.3 (4.5-nr) | 1.58 (0.81–3.10) | 0.180 |
| Other | 6 | 6 | 10.4 (1.1–22.6) | 2.00 (0.89–4.51) | 0.094 | 5 | 12.4 (1.7-nr) | 1.90 (0.78–4.63) | 0.159 |
| MSKCC score | |||||||||
| Good | 98 | 70 | 21.4 (17.7–27.5) | 1.00 | 35 | 63.9 (44.5–75.2) | 1.00 | ||
| Intermediate | 199 | 161 | 12.1 (9.2–15.8) | 1.48 (1.12–1.97) | 0.006 | 134 | 27.1 (19.5–32.8) | 2.44 (1.68–3.55) | < 0.0001 |
| Poor | 38 | 29 | 5.7 (3.9–8.3) | 2.00 (1.29–3.09) | 0.002 | 24 | 8.7 (5.4–25.1) | 4.04 (2.39–6.82) | < 0.0001 |
| Good | 98 | 70 | 21.4 (17.7–27.5) | 1.00 | 35 | 63.9 (44.5–75.2) | 1.00 | ||
| Intermediate+Poor | 237 | 190 | 10.6 (8.2–13.4) | 1.55 (1.17–2.03) | 0.002 | 158 | 23.8 (16.8–28.1) | 2.59 (1.79–3.74) | < 0.0001 |
| IMDC score | |||||||||
| Good | 117 | 84 | 21.4 (17.2–26.5) | 1.00 | 48 | 56.6 (38.6–75.2) | 1.00 | ||
| Intermediate | 176 | 139 | 13.3 (9.2–17.4) | 1.43 (1.09–1.87) | 0.010 | 109 | 29.4 (24.0–36.0) | 1.99 (1.41–2.80) | < 0.0001 |
| Poor | 42 | 37 | 4.0 (2.7–5.2) | 5.09 (3.39–7.66) | < 0.0001 | 36 | 5.3 (3.7–8.0) | 11.12 (6.95–17.80) | < 0.0001 |
| Good | 117 | 84 | 21.4 (17.2–26.5) | 1.00 | 48 | 56.6 (38.6–75.2) | 1.00 | ||
| Intermediate+Poor | 218 | 176 | 9.4 (7.5–12.4) | 1.65 (1.27–2.15) | 0.0002 | 145 | 23.7 (14.6–28.1) | 2.42 (1.74–3.36) | < 0.0001 |
| SII baseline | |||||||||
| < 730 | 209 | 153 | 18.7 (14.7–22.8) | 1.00 | 99 | 43.6 (35.3–52.1) | 1.00 | ||
| ≥ 730 | 126 | 107 | 6.3 (5.5–8.9) | 1.84 (1.43–2.36) | < 0.0001 | 94 | 13.5 (9.8–18.5) | 2.36 (1.78–3.14) | < 0.0001 |
Abbreviations: CI, Confidence Interval; ECOG, Eastern Cooperative Oncology Group; HR, Hazard Ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC, Memorial Sloan Kettering Cancer Center; n., number; OS, Overall Survival; PFS, Progression Free Survival; pts, patients; PS, Performance Status, SII, Systemic Immune Inflammation Index.